drugset
drugset / Trial / NCT00622245

Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

NCT00622245 ↗

Phase 2 Terminated 166 enrolled H. Lundbeck A/S
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of different doses of Lu AA34893 in the treatment of depression in patients with bipolar disorder.

Timeline

Start
2008-01
Primary completion
2009-01
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AA34893 Unknown 4 mg Oral
Subject Lu AA34893 Unknown 12 mg Oral
Subject Lu AA34893 Unknown 18 mg Oral
Subject Quetiapine Small molecule 300 mg Oral

Indications

bipolar depression